NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia Patients

CompletedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Acute Lymphoblastic Leukemia

Countries: United States, Australia, Canada, China, France, Israel, Italy, Netherlands

The aim of this study was to collect existing information from the medical charts of patients enrolled in the ongoing asciminib Managed Access Program (MAP) to better understand the effectiveness and safety of asciminib when used to treat adult patients with Ph+ ALL who are refractory, resistant or intolerant to available treatments.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

* Adult patients enrolled in the asciminib MAP.
* Diagnosis of Ph+ ALL.
* Patients received at least one dose of asciminib through the asciminib MAP.
* Appropriate approval obtained for the use of patient data including:

  * Signed informed consent form (ICF), or
  * ICF waiver granted by an Institutional review board/Independent Ethics Committee (IRB/IEC).

Exclusion criteria

• Age \< 18 years at the time of initiating asciminib treatment.

Locations (18)

Boston, Massachusetts, United States
Sydney, New South Wales, Australia
Montreal, Canada
Hong Kong, China
Le Chesnay, France
Ramat Gan, Israel
Ascoli Piceno, Italy
Bari, Italy
Catania, Italy
Cuneo, Italy
Pescara, Italy
Torino, Italy
Rotterdam, Netherlands
Islamabad, Pakistan
Rawalpindi, Pakistan
Bialystok, Poland
Madrid, Spain
London, United Kingdom